Stay updated with breaking news from Otonomy Inc. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Toward the end of trading Monday, the Dow traded up 0.40% to 31,621.04 while the NASDAQ fell 1.57% to 13,656.22. The S&P also fell, dropping 0.28% to ...
The strongest catalysts for a pharma stock are the various milestones on the road to FDA approval for new drugs. For new investors, they’ll often see a stock rise astronomically, but, when they go to make sense of the reasons for the jump, they’re greeted with unfamiliar acronyms. Let... Read More...
17 An all inclusive Cholesteatoma market report gives essential information, objective insights regarding international market trends and leads, competitor analysis, and much more. All the teams involved in building this market research report including consultants, market researchers, and data providers work hand-in-hand to generate more insightful data. Traditional research methodologies are supplemented with pioneering approaches to offer evidence-based insights via this market research report. The Cholesteatoma business report provides industry players with crucial support to expand the...
SAN DIEGO (AP) _ Otonomy Inc. (OTIC) on Thursday reported a loss of $10.6 million in its...
BioXcel Therapeutics Inc (NASDAQ: BTAI) plans to finalize study design, dosing, and endpoints for its BXCL501 Phase 3 program in dementia-related agitation. The end of the Phase 2 meeting with the FDA is scheduled in Q2 2021. BXCL501 is an orally dissolving thin film formulation of... Read More...